1. Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. Page - 4229-4231.
2. E Michael Lewiecki. Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect. US National Library of Medicines, National Institutes of Health. 15 Jun 2010. [Accessed 21 Dec 2020] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2899787/
3. Dennis M Black 1, Pierre D Delmas, Richard Eastell, Ian R Reid, Steven Boonen, Jane A Cauley, Felicia Cosman, Péter Lakatos, Ping Chung Leung, Zulema Man, Carlos Mautalen, Peter Mesenbrink, Huilin Hu, John Caminis, Karen Tong, Theresa Rosario-Jansen, Joel Krasnow, Trisha F Hue, Deborah Sellmeyer, Erik Fink Eriksen, Steven R Cummings, HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. NIH: National Library of Medicine, National center of biotechnology Information Pubmed.gov. 3 May 2007. [Accessed 21 Dec 2020] https://pubmed.ncbi.nlm.nih.gov/17476007/
4. Dr. Reddy’s Laboratories (UK) Ltd; Electronic Medicines Compendium (EMC); [Revised on Jan 2020] [Accessed 21 Dec 2020] https://www.medicines.org.uk/emc/files/pil.3623.pdf